載入...
Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity: The TOWER study
OBJECTIVE: To evaluate safety (primary objective) and efficacy of increasing doses (400 U up to 800 U) of incobotulinumtoxinA (Xeomin, Merz Pharmaceuticals GmbH) for patients with limb spasticity. METHODS: In this prospective, single-arm, dose-titration study (NCT01603459), patients (18–80 years) wi...
Na minha lista:
發表在: | Neurology |
---|---|
Main Authors: | , , , , , , , , , , , , , |
格式: | Artigo |
語言: | Inglês |
出版: |
Lippincott Williams & Wilkins
2017
|
主題: | |
在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5379931/ https://ncbi.nlm.nih.gov/pubmed/28283596 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0000000000003789 |
標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|